Eliminating NTDs Project

Eliminate sleeping sickness and improve the management of Leishmaniasis, Buruli Ulcer and Chagas Disease.

Sanofi and WHO Partnership

Sanofi and the WHO signed a first 5-year partnership to combat sleeping sickness in 2001. A third 5-year agreement was signed in 2011 with the goal to eliminate sleeping sickness and improve the management of leishmaniasis, Buruli ulcer and Chagas disease. Sanofi committed the same amount of financial backing (25 MUSD) and drug donations, bringing its total contribution to USD 75 million over 15 years (2001-2016).

These funds are dedicated to diseases management and control programs, including screening of population of endemic areas, medical staff training, disease awareness campaigns, logistics and infrastructure and surveillance of resistance to treatments.

Partnership objectives:

  • Control and elimination of the most "neglected" of the Neglected Tropical Diseases (NTDs)—Sleeping Sickness, Chagas disease, Buruli Ulcer, Leishmaniasis.
  • Eliminate Sleeping Sickness by 2020.


  • Sanofi

    Goods Supplier
    Canada | Staff size: Unknown

    Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, the world's fourth-largest by prescription sales. Sanofi engages in the research and development,...

  • World Health Organization (WHO)

    Funding Agencies
    Staff size: 5001-10,000

    WHO (World Health Organisation) is the directing and coordinating authority for health within the United Nations system. It is responsible for providing leadership on global health matters,...

More Resources

Key Information

LocationNorth Africa and Middle East, Tunisia, Togo, Senegal, Niger, Morocco, Mauritania, Mali, Iran, Guinea, Ghana, Cote d Ivoire, Colombia, Central African Republic, Cameroon, Burkina Faso, Brazil, Benin, Argentina, Algeria, Afghanistan, West Africa, Latin America and Caribbean, Central Africa
  • Start Date 2001